Rare nucleated fetal cells circulate within maternal blood. Noninvasive prenatal diagnosis by isolation and genetic analysis of these cells is currently being undertaken. We sought to determine if genetic evidence existed for persistent circulation of fetal cells from prior pregnancies. Venous blood samples were obtained from 32 pregnant women and 8 nonpregnant women who had given birth to males 6 months to 27 years earlier. Mononuclear cells were sorted by flow cytometry using antibodies to CD antigens 3, 4, 5, 19, 23, 34, and 38. DNA within sorted cells, amplified by PCR for Y chromosome sequences, was considered predictive of a male fetus or evidence of persistent male fetal cells. In the 32 pregnancies, male DNA was detected in 13 of 19 women carrying a male fetus. In 4 of 13 pregnancies with female fetuses, male DNA was also detected. All of the 4 women had prior pregnancies; 2 of the 4 had prior males and the other 2 had terminations of pregnancy. pearance. In a group of 20 primigravidas sampled on more than one occasion postpartum, quinacrine fluorescent signals ("Y body") were seen at a frequency of 0.01-0.1% of lymphocytes. These frequencies were noted to remain "practically unchanged" up until 1 year after delivery, when the study ended. In a related study, Ciaranfi et al. (5) (4) to include samples from women 5-7 years postpartum (5). In a series of 62 women who delivered a male infant, more than half had detectable male lymphocytes 2 years after birth. In some cases, metaphases with a Y chromosome were visualized 5 years postpartum. These studies, although intriguing, were performed in the 1970s using techniques less sensitive and less accurate than those available today.
Multiple investigators have now confirmed the existence of fetal cells in maternal blood, a finding first clearly demonstrated by Herzenberg et al. (1) in 1979, by fluorescenceactivated cell sorting of fetal cells bearing uniquely paternally inherited cell surface antigens. More recently, molecular genetic techniques such as PCR and fluorescence in situ hybridization have enhanced the detection of fetal-specific gene sequences in candidate fetal cells isolated from maternal blood, as summarized in recent review articles (2, 3) . A multicenter clinical evaluation, comparing the diagnostic accuracy of genetic analysis of fetal cells circulating in maternal blood with cells obtained by amniocentesis or chorionic villus sampling, is currently being funded by the National Institutes of Health. The question of whether fetal cells in maternal blood originate from a current or prior pregnancy is important, not only as it pertains to diagnostic considerations but also as a fundamental issue in reproductive immunobiology.
Schroder et al. (4) originally described the persistence of fetal leukocytes in the maternal circulation after delivery. In this important observation, interphase Y body fluorescence was used to determine the frequency of male fetal cells in maternal blood and the kinetics of their subsequent disapThe publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact.
pearance. In a group of 20 primigravidas sampled on more than one occasion postpartum, quinacrine fluorescent signals ("Y body") were seen at a frequency of 0.01-0.1% of lymphocytes. These frequencies were noted to remain "practically unchanged" up until 1 year after delivery, when the study ended. In a related study, Ciaranfi et al. (5) extended the observations of Schroder et al. (4) to include samples from women 5-7 years postpartum (5) . In a series of 62 women who delivered a male infant, more than half had detectable male lymphocytes 2 years after birth. In some cases, metaphases with a Y chromosome were visualized 5 years postpartum. These studies, although intriguing, were performed in the 1970s using techniques less sensitive and less accurate than those available today.
During this decade, investigators using PCR amplification of Y chromosome-specific sequences to identify fetal cells in maternal blood noted "false positive" results-i.e., detection of male DNA when the fetus was female (6, 7) . Although laboratory contamination as a source of true false positives can be a concern (8) , it appears that, in some cases, the male DNA was a real finding, possibly originating from a prior pregnancy (9) . Other investigators studied postpartum maternal samples without using cell separation techniques to enrich for specific subpopulations of fetal cells and concluded that fetal cells did not persist postpartum (10) .
The study reported here occurred in two parts. Initially, we used a monoclonal antibody to cluster differentiation antigen (CD) 34 to isolate fetal hematopoietic stem cells from the blood of pregnant women. The surprising results, described below, suggested that the gender of the circulating CD34+ cells did not always correlate with the fetal gender of the current pregnancy. This led to the hypothesis that fetal CD34+ cells could persist from a prior pregnancy. We tested this hypothesis by fluorescence-activated cell sorting of four specific subpopulations of mononuclear cells from women who were not presently pregnant but who had previously given birth to a male infant. Although we were initially interested in the immunophenotypic identification of the persisting fetal cells because of the potential for diagnostic errors in prenatal genetic diagnosis, our results suggest a broader significance. Pregnancy may establish a long-term, low-grade chimeric state in the human female.
METHODS
Patients. In the initial study, venous blood samples (20 ml) were obtained in EDTA or citrated dextrose solution A (ACDA) from 32 pregnant women (9.5-19 weeks of gestation) prior to genetic amniocentesis for advanced maternal age. In the second phase of the study, venous blood samples (20 ml) (11) . The details of the PCR amplification, separation by electrophoresis, Southern transfer, and hybridization have been described (6) . Autoradiographs were interpreted as positive or negative for the presence of the amplified 291-or 397-bp fragment before the results of the fetal gender were known from prenatal cytogenetic analysis. The presence of the amplified fragment was considered predictive of a male fetus.
In the interval between the first and second phases of the study, we became aware of the application of nested PCR to the detection of rare cells (7) . This technique has the advantage of suppressing nonspecific background amplification, permitting detection of rare cell populations without requiring Southern transfer and hybridization to detect a PCR product. In the second phase of the study, the sorted cells were boiled. Individual PCRs were set up according to the method of Lo et al. (7), using the previously reported external primers Y 1.5 and 1.6. After initial PCR for 40 cycles, a 2-,lA aliquot of the first reaction was added to a second reaction using the flanking primers Y 1.7 and 1.8 (7). The second reaction proceeded for 25 cycles. Amplification products were analyzed on a 2% agarose gel for the presence of a 198-bp product.
RESULTS
The results of the initial study are listed in Table 1 . Of the 32 pregnancies, 19 had male and 13 had female fetuses. The male-specific amplification product was detected in 17 sorted samples amplified before fetal gender was determined by prenatal karyotype. Of the 17 fetuses predicted to be male, 13 were male and 4 were female as determined from results of cytogenetic studies on amniocytes. In the four false positive cases, there was no evidence of PCR contamination in the reagent control. Review of the prior pregnancy histories of these four women indicated that two of the women each had one male infant prior to sampling for the current study. The other two women had two and four elective terminations, respectively, prior to the current pregnancy with a female fetus.
The results of the study involving the nonpregnant women are shown in Table 2 . There was no evidence of false positive amplification in reagent controls or female cells sorted prior to experimental samples. No male DNA was detected in cells expressing the B-cell antigen CD19 or CD23. One woman had detectable male DNA in her CD3+ as well as her CD34+CD38+ cells. Male DNA was detected in the sorted CD34+CD38+ cells from six of the eight women (Fig. 1) . Male DNA was not detected in the women who had most recently delivered males (6 and 10 months prior to sampling). The persistence of male CD34+CD38+ cells was demonstrated in the woman who had delivered her last son 27 years prior to sampling.
DISCUSSION
We have presented data on four women who were pregnant with female fetuses and six women who were not pregnant that demonstrate the continued circulation of male CD34+ or CD34+CD38+ cells from a previous pregnancy. Although controversy exists in the literature regarding the exact length of time that male DNA can be detected in postpartum blood samples obtained from women who delivered male infants (range of 3-8 months) (9, 10) , these previous studies were performed on unpurified maternal DNA. In the present study, we utilized the fluorescence-activated cell sorter to isolate specific subpopulations of cells. The results cannot be compared to previous studies because we selectively amplified only The results are significant because they identify a potential diagnostic complication for genetic analysis using fetal cells circulating in maternal blood, the persistence of cells from a prior pregnancy. If fetal cells are to be used for genetic diagnosis, several strategies should be employed to be certain that the cells being analyzed derive from the current pregnancy. Depletion methods that selectively remove T cells, CD34+, or CD34+CD38+ cells could be incorporated into fetal cell isolation protocols. Alternatively, positive selection methods could be directed toward a highly differentiated fetal cell type that is unlikely to proliferate, such as the fetal nucleated erythrocyte (12) . Both methods may become necessary to ensure diagnostic accuracy.
In this study, male cells were detected qualitatively by the PCR amplification of Y chromosome-specific sequences. No attempts were made to quantify the number of male cells detected in the samples obtained from the pregnant or nonpregnant women. The fact that the persisting cells were detected only by Southern hybridization or nested PCR techniques implies that they are extremely rare and probably circulate in maternal blood at much lower frequencies than Schroder et al. (4) originally suggested. We have independently described techniques of fetal cells quantitation by PCR that might be applied to future experiments to address the question of frequency (13) .
The fact that male CD34+CD38+ cells were detectable as long as 27 years after the birth of a male infant was unexpected. An analogous situation has been described in the mouse, using a uniquely paternal cytogenetic marker chromosome, T6, that is transmitted to offspring. Gaillard et al. (14) demonstrated that during murine pregnancy, there was a considerable concentration of fetal cells bearing the T6 chromosome in the maternal spleen (3-6% of total cells). Additionally, these cells were shown to be capable of division, survived postpartum, and increased in number in a second pregnancy. The term "microchimerism" has been proposed to describe the apparently stable long-term survival and proliferation of allogeneic fetal cells in the maternal mouse without induction of graft versus host disease (15) (16) (17) (18) lation is the first step in the acquisition of donor-specific tolerance and, ultimately, successful graft acceptance. The human pregnancy may also benefit from similar one-way or even two-way traffic.
The development of microchimerism in human pregnancies needs to be further investigated in larger numbers of multiparous women. Fetal cells could be engrafting in maternal lymphoid organs or bone marrow. Alternatively, the progenitor cells could remain in the circulation and continue to divide for years. These hypotheses could be tested by obtaining blood and bone marrow samples from women who have had chromosomally abnormal fetuses. Important questions need to be asked, such as what is the clinical significance, if any, of becoming chimeric? Is there any evidence of low-grade, chronic, graft versus host disease in parous women due to microchimerism? Is there any relationship between pregnancy and the subsequent development of autoimmune disorders? The eight nonpregnant women described here were all healthy. The ability to detect rare populations of fetal cells via sensitive techniques such as fluorescence-activated cell sorting and PCR will permit further exploration of these important issues.
